This program supports bench to bedside research for developing novel drug therapies for the treatment of neurologic and neurocognitive complications of HIV infection. The program supports: (1) preclinical to clinical research on existing and novel drug targets; (2) development of novel approaches for delivering drugs, including antiretrovirals to the central nervous system (CNS); and (3) creative and original research that has as its goal the movement of new treatments and therapeutic strategies to the clinic. In addition, the program encourages basic and clinical studies on neurotoxicities related to highly active antiretroviral therapy.
Areas of Emphasis
- Identify novel therapeutic agents, delivery approaches (nanotechnology) and targets, including adjunctive neuroprotective strategies to treat HIV-induced neurologic and neurocognitive complications of HIV infection.
- Develop strategies for eradication of persistent HIV reservoirs in the CNS.
- Develop or validate research models, with particular emphasis on using simian immunodeficiency virus, of HIV-associated neurocognitive disorders that reflect chronic HIV infection, aging, and cardiovascular related neurodegenerative processes.
- Support discovery research to identify clinical biomarkers linked with HIV-associated CNS disease progression and response to therapy.
- Design and support clinical studies addressing nervous system complications of HIV infection.
Deborah Colosi, Ph.D.
6001 Executive Blvd, Room 6115D, MSC 9621